Pulse Biosciences (NASDAQ:PLSE) Sees Unusually-High Trading Volume – Still a Buy?

Pulse Biosciences, Inc (NASDAQ:PLSE) shares saw unusually-strong trading volume on Monday . Approximately 771,664 shares changed hands during trading, an increase of 150% from the previous session’s volume of 308,746 shares.The stock last traded at $20.2650 and had previously closed at $19.08.

Analyst Ratings Changes

PLSE has been the topic of a number of research reports. Oppenheimer reissued an “outperform” rating and issued a $30.00 price objective on shares of Pulse Biosciences in a report on Friday, February 20th. Wall Street Zen raised Pulse Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, February 21st. Mizuho set a $30.00 price objective on Pulse Biosciences in a report on Friday, February 6th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Pulse Biosciences in a report on Tuesday, April 21st. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $30.00.

Pulse Biosciences Stock Performance

The stock has a market capitalization of $1.30 billion, a PE ratio of -17.35 and a beta of 1.63. The firm’s fifty day moving average price is $20.85 and its two-hundred day moving average price is $17.59.

Pulse Biosciences (NASDAQ:PLSE) last posted its earnings results on Monday, May 4th. The company reported ($0.27) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.05. The firm had revenue of $0.40 million for the quarter, compared to analysts’ expectations of $0.25 million. As a group, sell-side analysts anticipate that Pulse Biosciences, Inc will post -1.29 earnings per share for the current fiscal year.

Insider Buying and Selling at Pulse Biosciences

In other news, insider Kevin Patrick Danahy sold 20,000 shares of Pulse Biosciences stock in a transaction that occurred on Friday, February 13th. The shares were sold at an average price of $23.53, for a total transaction of $470,600.00. Following the completion of the transaction, the insider directly owned 43,298 shares of the company’s stock, valued at $1,018,801.94. The trade was a 31.60% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Over the last ninety days, insiders have sold 65,000 shares of company stock worth $1,565,400. 74.60% of the stock is owned by insiders.

Hedge Funds Weigh In On Pulse Biosciences

Institutional investors have recently made changes to their positions in the company. Russell Investments Group Ltd. grew its holdings in Pulse Biosciences by 13.8% in the fourth quarter. Russell Investments Group Ltd. now owns 5,106 shares of the company’s stock valued at $70,000 after purchasing an additional 619 shares during the period. BNP Paribas Financial Markets grew its holdings in Pulse Biosciences by 63.6% in the second quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company’s stock valued at $26,000 after purchasing an additional 680 shares during the period. Alliancebernstein L.P. grew its holdings in Pulse Biosciences by 6.7% in the third quarter. Alliancebernstein L.P. now owns 20,620 shares of the company’s stock valued at $365,000 after purchasing an additional 1,300 shares during the period. Westside Investment Management Inc. grew its holdings in Pulse Biosciences by 2.9% in the fourth quarter. Westside Investment Management Inc. now owns 66,326 shares of the company’s stock valued at $911,000 after purchasing an additional 1,886 shares during the period. Finally, Tower Research Capital LLC TRC grew its holdings in Pulse Biosciences by 275.0% in the second quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company’s stock valued at $44,000 after purchasing an additional 2,156 shares during the period. 76.95% of the stock is owned by hedge funds and other institutional investors.

About Pulse Biosciences

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.